Comparison of two guideline-concordant antimicrobial combinations in elderly patients hospitalized with severe community-acquired pneumonia

Bryan Z. Wilson, Antonio Anzueto, Marcos I. Restrepo, Mary Jo V Pugh, Eric M. Mortensen

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

OBJECTIVE: Two of the guideline-concordant therapies for severe community-acquired pneumonia are either a beta-lactam and fluoroquinolone or beta-lactam and macrolide. However it is unclear if there is a benefit for one vs. The other for elderly patients with severe community-acquired pneumonia. DESIGN: A retrospective population-based cohort study of patients with community-acquired pneumonia. SETTING: Patients admitted to an intensive care unit of any Department of Veterans Affairs hospital during 5-yr period. PATIENTS: We included only those patients >65 yrs of age admitted to the intensive care unit with community-acquired pneumonia who received either beta-lactam + fluoroquinolone or beta-lactam + macrolide antibiotic therapy for pneumonia. INTERVENTION: Not applicable. MEASUREMENTS: We used multilevel regression models to examine the effect of beta-lactam + fluoroquinolone vs. beta-lactam + macrolide on each of the outcomes after adjusting for potential confounders using propensity scores. MAIN RESULTS: The cohort consisted of 1,989 patients: 98.5% male and a mean age of 74 yrs. For treatment, 44% of subjects received beta-lactam + fluoroquinolone and 56% received beta-lactam + macrolide. Unadjusted 30-day mortality was 27% for beta-lactam + fluoroquinolone and 24% for beta-lactam + macrolide (p = .11). In the multilevel models, the use of beta-lactam + fluoroquinolone was not significantly associated with 30-day mortality (odds ratio 1.05, 95% confidence interval 0.85-1.30). However, the use of beta-lactam + fluoroquinolone was significantly associated with increased mean length of stay (incidence rate ratio 1.30, 95% confidence interval 1.27-1.33). CONCLUSIONS: We found no significant difference for 30-day mortality but did demonstrate an association with increase in length of stay associated with the use of beta-lactam + fluoroquinolone. Randomized controlled trials are needed to determine the most effective antibiotics regimes for patients with severe pneumonia.

Original languageEnglish (US)
Pages (from-to)2310-2314
Number of pages5
JournalCritical Care Medicine
Volume40
Issue number8
DOIs
StatePublished - Aug 2012

Fingerprint

beta-Lactams
Pneumonia
Guidelines
Fluoroquinolones
Macrolides
Intensive Care Units
Mortality
Length of Stay
Confidence Intervals
Anti-Bacterial Agents
Veterans Hospitals
Propensity Score
Cohort Studies
Therapeutics
Randomized Controlled Trials
Odds Ratio

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine

Cite this

Comparison of two guideline-concordant antimicrobial combinations in elderly patients hospitalized with severe community-acquired pneumonia. / Wilson, Bryan Z.; Anzueto, Antonio; Restrepo, Marcos I.; Pugh, Mary Jo V; Mortensen, Eric M.

In: Critical Care Medicine, Vol. 40, No. 8, 08.2012, p. 2310-2314.

Research output: Contribution to journalArticle

@article{36f7214b6fc14532b4444c265c10022d,
title = "Comparison of two guideline-concordant antimicrobial combinations in elderly patients hospitalized with severe community-acquired pneumonia",
abstract = "OBJECTIVE: Two of the guideline-concordant therapies for severe community-acquired pneumonia are either a beta-lactam and fluoroquinolone or beta-lactam and macrolide. However it is unclear if there is a benefit for one vs. The other for elderly patients with severe community-acquired pneumonia. DESIGN: A retrospective population-based cohort study of patients with community-acquired pneumonia. SETTING: Patients admitted to an intensive care unit of any Department of Veterans Affairs hospital during 5-yr period. PATIENTS: We included only those patients >65 yrs of age admitted to the intensive care unit with community-acquired pneumonia who received either beta-lactam + fluoroquinolone or beta-lactam + macrolide antibiotic therapy for pneumonia. INTERVENTION: Not applicable. MEASUREMENTS: We used multilevel regression models to examine the effect of beta-lactam + fluoroquinolone vs. beta-lactam + macrolide on each of the outcomes after adjusting for potential confounders using propensity scores. MAIN RESULTS: The cohort consisted of 1,989 patients: 98.5{\%} male and a mean age of 74 yrs. For treatment, 44{\%} of subjects received beta-lactam + fluoroquinolone and 56{\%} received beta-lactam + macrolide. Unadjusted 30-day mortality was 27{\%} for beta-lactam + fluoroquinolone and 24{\%} for beta-lactam + macrolide (p = .11). In the multilevel models, the use of beta-lactam + fluoroquinolone was not significantly associated with 30-day mortality (odds ratio 1.05, 95{\%} confidence interval 0.85-1.30). However, the use of beta-lactam + fluoroquinolone was significantly associated with increased mean length of stay (incidence rate ratio 1.30, 95{\%} confidence interval 1.27-1.33). CONCLUSIONS: We found no significant difference for 30-day mortality but did demonstrate an association with increase in length of stay associated with the use of beta-lactam + fluoroquinolone. Randomized controlled trials are needed to determine the most effective antibiotics regimes for patients with severe pneumonia.",
author = "Wilson, {Bryan Z.} and Antonio Anzueto and Restrepo, {Marcos I.} and Pugh, {Mary Jo V} and Mortensen, {Eric M.}",
year = "2012",
month = "8",
doi = "10.1097/CCM.0b013e31825151a8",
language = "English (US)",
volume = "40",
pages = "2310--2314",
journal = "Critical Care Medicine",
issn = "0090-3493",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Comparison of two guideline-concordant antimicrobial combinations in elderly patients hospitalized with severe community-acquired pneumonia

AU - Wilson, Bryan Z.

AU - Anzueto, Antonio

AU - Restrepo, Marcos I.

AU - Pugh, Mary Jo V

AU - Mortensen, Eric M.

PY - 2012/8

Y1 - 2012/8

N2 - OBJECTIVE: Two of the guideline-concordant therapies for severe community-acquired pneumonia are either a beta-lactam and fluoroquinolone or beta-lactam and macrolide. However it is unclear if there is a benefit for one vs. The other for elderly patients with severe community-acquired pneumonia. DESIGN: A retrospective population-based cohort study of patients with community-acquired pneumonia. SETTING: Patients admitted to an intensive care unit of any Department of Veterans Affairs hospital during 5-yr period. PATIENTS: We included only those patients >65 yrs of age admitted to the intensive care unit with community-acquired pneumonia who received either beta-lactam + fluoroquinolone or beta-lactam + macrolide antibiotic therapy for pneumonia. INTERVENTION: Not applicable. MEASUREMENTS: We used multilevel regression models to examine the effect of beta-lactam + fluoroquinolone vs. beta-lactam + macrolide on each of the outcomes after adjusting for potential confounders using propensity scores. MAIN RESULTS: The cohort consisted of 1,989 patients: 98.5% male and a mean age of 74 yrs. For treatment, 44% of subjects received beta-lactam + fluoroquinolone and 56% received beta-lactam + macrolide. Unadjusted 30-day mortality was 27% for beta-lactam + fluoroquinolone and 24% for beta-lactam + macrolide (p = .11). In the multilevel models, the use of beta-lactam + fluoroquinolone was not significantly associated with 30-day mortality (odds ratio 1.05, 95% confidence interval 0.85-1.30). However, the use of beta-lactam + fluoroquinolone was significantly associated with increased mean length of stay (incidence rate ratio 1.30, 95% confidence interval 1.27-1.33). CONCLUSIONS: We found no significant difference for 30-day mortality but did demonstrate an association with increase in length of stay associated with the use of beta-lactam + fluoroquinolone. Randomized controlled trials are needed to determine the most effective antibiotics regimes for patients with severe pneumonia.

AB - OBJECTIVE: Two of the guideline-concordant therapies for severe community-acquired pneumonia are either a beta-lactam and fluoroquinolone or beta-lactam and macrolide. However it is unclear if there is a benefit for one vs. The other for elderly patients with severe community-acquired pneumonia. DESIGN: A retrospective population-based cohort study of patients with community-acquired pneumonia. SETTING: Patients admitted to an intensive care unit of any Department of Veterans Affairs hospital during 5-yr period. PATIENTS: We included only those patients >65 yrs of age admitted to the intensive care unit with community-acquired pneumonia who received either beta-lactam + fluoroquinolone or beta-lactam + macrolide antibiotic therapy for pneumonia. INTERVENTION: Not applicable. MEASUREMENTS: We used multilevel regression models to examine the effect of beta-lactam + fluoroquinolone vs. beta-lactam + macrolide on each of the outcomes after adjusting for potential confounders using propensity scores. MAIN RESULTS: The cohort consisted of 1,989 patients: 98.5% male and a mean age of 74 yrs. For treatment, 44% of subjects received beta-lactam + fluoroquinolone and 56% received beta-lactam + macrolide. Unadjusted 30-day mortality was 27% for beta-lactam + fluoroquinolone and 24% for beta-lactam + macrolide (p = .11). In the multilevel models, the use of beta-lactam + fluoroquinolone was not significantly associated with 30-day mortality (odds ratio 1.05, 95% confidence interval 0.85-1.30). However, the use of beta-lactam + fluoroquinolone was significantly associated with increased mean length of stay (incidence rate ratio 1.30, 95% confidence interval 1.27-1.33). CONCLUSIONS: We found no significant difference for 30-day mortality but did demonstrate an association with increase in length of stay associated with the use of beta-lactam + fluoroquinolone. Randomized controlled trials are needed to determine the most effective antibiotics regimes for patients with severe pneumonia.

UR - http://www.scopus.com/inward/record.url?scp=84864278373&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864278373&partnerID=8YFLogxK

U2 - 10.1097/CCM.0b013e31825151a8

DO - 10.1097/CCM.0b013e31825151a8

M3 - Article

C2 - 22622401

AN - SCOPUS:84864278373

VL - 40

SP - 2310

EP - 2314

JO - Critical Care Medicine

JF - Critical Care Medicine

SN - 0090-3493

IS - 8

ER -